If You Invested in Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics, Inc. (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. According to multiple company disclosures, Avenue is developing drug candidates that target serious conditions of the central nervous system and acute pain. The company is classified in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector.

Avenue Therapeutics states that it is headquartered in Miami, Florida and that it was founded by Fortress Biotech, Inc. Avenue’s common stock has been listed on the Nasdaq Capital Market under the symbol ATXI during the periods described in the company’s news releases, and more recent SEC filings indicate that Avenue’s common stock trades on the OTC Markets Group under the symbol ATXI.

Business focus and therapeutic areas

Avenue describes itself as a company dedicated to neurologic diseases. Its pipeline, as outlined in recent press releases, includes three main assets:

• AJ201, described as a novel, first-in-class asset in development for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s disease. Company materials explain that AJ201 is being evaluated in a Phase 1b/2a multicenter, randomized, double-blind clinical trial in patients with SBMA, with primary endpoints focused on safety and tolerability and additional pharmacokinetic and pharmacodynamic measures.
• BAER-101, described by Avenue as an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for central nervous system (CNS) diseases. Company communications state that preclinical mouse models have shown BAER-101’s ability to fully suppress seizure activity in certain epilepsy models, and Avenue has discussed plans, subject to financing, to initiate a Phase 2a clinical trial in focal epilepsy and other seizure disorders. In later disclosures, Avenue reports that its majority-owned subsidiary Baergic Bio, Inc., which held BAER-101, was acquired by Axsome Therapeutics, Inc., and that Axsome received worldwide commercial, development, and manufacturing rights to BAER-101 (to be referred to as AXS-17). Avenue expects to receive a substantial portion of potential future milestone and royalty payments related to AXS-17.
• Intravenous (IV) tramadol, which Avenue reports is in Phase 3 clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Company disclosures describe an agreed Phase 3 safety study design with the U.S. Food and Drug Administration (FDA), involving randomization of post-bunionectomy patients to IV tramadol or IV morphine with access to rescue medication.

Across its communications, Avenue emphasizes that it currently has no drug products for sale and that its prospects depend on obtaining regulatory approvals and successfully commercializing its product candidates or partnering them.

Clinical development approach

Avenue’s public materials describe a development strategy centered on clinical trials and regulatory engagement. For AJ201, the company details a 12-week, multicenter, randomized, double-blind Phase 1b/2a trial in SBMA, with safety and tolerability as the primary endpoint. Secondary endpoints include pharmacokinetic and pharmacodynamic data such as changes in mutant androgen receptor protein levels in skeletal muscle and expression of Nrf2-activated genes, while exploratory objectives include MRI-based measures of fat and muscle composition.

For BAER-101, Avenue highlights preclinical in vivo data in genetic epilepsy models and notes its intent, subject to financing or partnership, to advance into a Phase 2a clinical trial in patients with seizure disorders. For IV tramadol, Avenue reports that it reached final agreement with the FDA on a Phase 3 safety study protocol and statistical analysis plan, with a proposed design involving comparison to IV morphine in a postoperative pain setting.

Corporate structure and affiliations

Company disclosures state that Avenue Therapeutics was founded by Fortress Biotech, Inc., and that Fortress controls a majority of the voting power of Avenue’s outstanding capital stock. Avenue has also reported the existence of a majority-owned subsidiary, Baergic Bio, Inc., which held rights to BAER-101 prior to its acquisition by Axsome Therapeutics. Avenue’s filings note that it relies on third parties for several aspects of its operations and that it has entered into license agreements for key assets, including an exclusive license for AJ201 from AnnJi Pharmaceuticals for specified territories.

Regulatory and listing status

In its news releases, Avenue has discussed matters related to its stock listing, including a 1-for-75 reverse stock split of its common stock and efforts to comply with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Later, an SEC Form 8-K indicates that Avenue’s common stock is registered under Section 12(g) of the Securities Exchange Act of 1934 and trades on the OTC Markets Group under the symbol ATXI, while noting that there are no securities registered under Section 12(b).

Risk factors highlighted by the company

Avenue’s press releases and SEC filings contain detailed forward-looking statements and risk factor summaries. The company notes, among other points, that it has incurred significant losses since inception, expects to continue to incur losses, and faces substantial doubt about its ability to continue as a going concern. It emphasizes dependence on additional funding, potential delays or failures in obtaining regulatory approvals, reliance on third-party data and partners, exposure to product liability risk, and the possibility that government or third-party payors may not provide adequate coverage or payment rates for any future approved products.

Position within the pharmaceutical preparation manufacturing industry

Within the pharmaceutical preparation manufacturing industry, Avenue positions itself as a specialty pharmaceutical company focused on neurologic diseases, including rare neuromuscular disorders such as SBMA and CNS conditions such as epilepsy, as well as acute postoperative pain. Its disclosures emphasize the development of assets that target specific mechanisms, such as Nrf1 and Nrf2 activation and androgen receptor degradation for AJ201, selective GABAA α2, α3 modulation for BAER-101, and IV tramadol for acute pain management in supervised settings.

FAQs about Avenue Therapeutics (ATXI)